D. Andrew Loblaw, MD, MSc, FRCPC
Odette Cancer Centre
Dr. Loblaw Medicine Professional Corp: President: Employee
AbbVie: Consultant, Honoraria; Astellas: Advisory Board, Consultant, Honoraria, Travel Expenses; Bayer: Consultant, Honoraria; Bristol-Myers Squibb: Consultant; Ferring: Consultant; Glaxo Smith Kline: Consultant; Janssen: Advisory Board, Honoraria; Janssen Oncology: Consultant, Travel Expenses; Merck: Consultant; Novartis: Consultant; Roche: Consultant; TerSera: Honoraria
Sunnybrook Research Institute: Patent/License Fees/Copyright
Prostate Cure Foundation: Founder and Chair
Dr Andrew Loblaw is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto.
He received a Bachelor of Science in Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University. He completed his specialty training in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from Royal College’s Clinician Investigator Program all at the University of Toronto.
Dr Loblaw’s clinical practice and research interest focus on improving outcomes for men with prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and dissemination of evidence-based guidelines and in image-guided radiotherapy.
Dr Loblaw is an Ontario Association of Radiation Oncology Clinician Scientist and a Scientist at the Sunnybrook Research Institute. A Fellow of the American Society of Clinical Oncology (FASCO), he was previous Co-Chair of the ASCO’s Genitourinary Advisory Group and remains Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care.
Sunday, October 21
5:21 PM – 5:39 PM
Tuesday, October 23
6:05 PM – 6:15 PM
Wednesday, October 24
2:30 PM – 2:40 PM